The relationship between clinical and molecular characteristics of 45 treated individuals with histologically-documented human immunodeficiency virus (HIV)-associated B-cell nonHodgkin's lymphoma was examined t o determine whether differences in molecular features of lymphoma were associated with dtferences in clinical outcome. Tissue specimens from these tumors were evaluated for evidence of lg heavychain gene rearrangements using both Southern blot analysis and reverse transcriptase polymerase chain reaction (RT-PCR). Lymphomas were also evaluated for the presence of Epstein-Barr virus (EBV) DNA sequences and omyc gene rearrangements. Twenty-five lymphomas were characterized as polyclonal and 20 as monoclonal. PCR amplification of expressed Ig variable (V)-region genes confirmed polyclonality in three extensively studied polyclonal lymphomas. The median CD4 count was significantly higher in the group with polyclonal disease (277/pL) than in the group with monoclonal disease (123/pL), P = .04. The complete response rate t o therapy was significantly higher in patients with polyclonal disease (78%) and CD4 greater than 200/pL NTERMEDIATE-OR HIGH-GRADE B-cell lymphoma occurs in 5% to 10% of human immunodeficiency virus (H1V)-infected individuals,13* and may account for 8% to 27% of all lymphoma diagnosed in the United States. The clinical characteristics of HIV-associated lymphoma are well described in the literat~re.~.~ Patients with HIV-associated lymphoma typically present with advanced extranodal disease and most die less than I year from the time of diagnosis. It is useful to distinguish patients with HIV-associated primary central nervous system lymphoma who have profound immunosuppression from those with systemic lymphoma who have more variable levels of immunosuppression at the time of diagnosi~.~,~
The relationship between clinical and molecular characteristics of 45 treated individuals with histologically-documented human immunodeficiency virus (HIV)-associated B-cell nonHodgkin's lymphoma was examined t o determine whether differences in molecular features of lymphoma were associated with dtferences in clinical outcome. Tissue specimens from these tumors were evaluated for evidence of lg heavychain gene rearrangements using both Southern blot analysis and reverse transcriptase polymerase chain reaction (RT-PCR). Lymphomas were also evaluated for the presence of Epstein-Barr virus (EBV) DNA sequences and omyc gene rearrangements. Twenty-five lymphomas were characterized as polyclonal and 20 as monoclonal. PCR amplification of expressed Ig variable (V)-region genes confirmed polyclonality in three extensively studied polyclonal lymphomas. The median CD4 count was significantly higher in the group with polyclonal disease (277/pL) than in the group with monoclonal disease (123/pL), P = .04. The complete response rate t o therapy was significantly higher in patients with polyclonal disease (78%) and CD4 greater than 200/pL NTERMEDIATE-OR HIGH-GRADE B-cell lymphoma occurs in 5% to 10% of human immunodeficiency virus (H1V)-infected individuals,13* and may account for 8% to 27% of all lymphoma diagnosed in the United States. The clinical characteristics of HIV-associated lymphoma are well described in the literat~re.~.~ Patients with HIV-associated lymphoma typically present with advanced extranodal disease and most die less than I year from the time of diagnosis. It is useful to distinguish patients with HIV-associated primary central nervous system lymphoma who have profound immunosuppression from those with systemic lymphoma who have more variable levels of immunosuppression at the time of diagnosi~.~,~
We have previously identified clinical features predictive of improved survival in patients with HIV-associated systemic lymph~rna.~ The most important predictor of survival was the absolute number of CD4+ lymphocytes per microliter of blood at the time of diagnosis, for which there was a direct relationship with survival. Other features associated with improved survival included lack of a prior acquired immunodeficiency disease syndrome (AIDS)-defining opportunistic infection, higher performance score and the absence of an extranodal site of disease. Patients treated with chemotherapy regimens containing lower doses of cyclophosphamide (< 1 g/m2) also had prolonged survival. These findings have been confirmed by others* who have identified bone marrow involvement as being a specifically poor prognosis extranodal site.
We have recently shown heterogeneity in the molecular characteristics of HIV-associated non-Hodgkin's lymphoma (NHL) in an analysis of biopsy specimens obtained from patients presenting at UCSFBFGH between 1986 and 1991.1° In this study clonality, infection with Epstein-Barr virus (EBV), and the presence of a rearranged c-myc gene were determined by Southern blot analysis. This extensive (81%) than in those with monoclonal disease (31%) and CD4 less than 200/pL (33%). CD4 count, clonality, and presence of EBV DNA sequences were the most important predictors of survival. Both Kaplan-Meier and Cox proportional hazards analyses showed a markedly prolonged survival in those patients with both CD4 z 200/pL and polyclonal disease.
Histologically the polyclonal lymphomas were high grade in appearance and contained prominent macrophages. All seven surviving patients were in this group. Median survival for those individuals whose tumors contained EBV sequences was only 3.2 months (range, 0.4 t o 19.5). whereas those with EBV-tumors survived for a median of 9.0 months (range, 0.7 t o 65.2). P = .0007. These data indicate that molecular features of HIV-associated lymphomas may be important predictors of clinical outcome. These characteristics define a distinct subset of patients with polyclonal EBVtumors and CD4 counts greater than 200/pL that appear t o have a less aggressive clinical course.
0 1995 by The American Society of Hematology. molecular characterization showed polyclonal, EBV-tumors without c-myc rearrangements to be the most prevalent genotype (14 of 40; 35%). Monoclonal EBV' tumors with no evidence of c-myc rearrangement were the second most prevalent class (10 of 40; 25%), and polyclonal EBV' tumors were observed in only a small subset of specimens (3 of 40; 8%). The finding of polyclonality based upon immunohistochemical staining or Ig gene rearrangement in a substantial proportion of lymphomas from HIV-infected individuals has recently been confirmed by investigators in three other laboratories."-"
The finding of polyclonality closely resembles observations made in transplant-associated lymphoma^'^,'^; however, the frequent absence of EBV in these HIV-associated polyclonal tumors1".16 sets them apart from the transplant-associated tumors that are uniformly EBV+.'4,'7 The current study is an analysis of the clinical characteristics of treated patients, some of whose biopsy specimens were analyzed in the previous molecular study.'" To determine whether differences in the molecular features of lymphoma are associated with differences in clinical characteristics or outcome, we examined the relationship between molecular and clinical data obtained from a group of 45 patients with HIV-associated NHL in whom adequate tissue was available for molecular analysis. In addition, new molecular studies using RT-PCR were performed to further confirm the absence of clonal Ig gene rearrangements in a subset of these polyclonal specimens.
PATIENTS AND METHODS

Patient population.
A total of 164 HIV-seropositive individuals were diagnosed with intermediateor high-grade systemic B-cell NHL and subsequently treated at San Francisco General Hospital between 1983 and 1991. Forty five of these patients had histologically-documented disease and an adequate amount of frozen tissue available for molecular analysis. These 45 cases were included in this investigation. Untreated patients were excluded from the study to eliminate treatment-related bias. Peripheral blood T-cell phenotypic data obtained at the time of diagnosis was available in 39 patients.
In all cases, therapy was instituted within 1 week of diagnosis. Treatment regimens included (1) CHOP: cyclophosphamide I g/m2 on day 1, doxorubicin 40 mg/m2 on day I, vincristine 1.4 mg/m2 on day I, prednisone 100 mg/m2 on days 1 through 5; (2) m-BACOD": methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone; (3) reduced-dosage m-BACOD"; (4) CVP'": cyclophosphamide, vincristine, prednisone; (5) COMET-A': cyclophosphamide, vincristine, methotrexate, etoposide, high-dose cytosine arabinoside; and (6) radiotherapy. Some individuals received adjunctive therapy with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) or recombinant human granulocyte colony-stimulating factor (rhG-CSF) either because of participation in clinical trials that used these agents or because their use was indicated in prevention or treatment of severe granulocytopenia. Follow-up data was collected through each patient's last clinic visit in 1993.
The diagnosis of lymphoma was made by traditional surgical pathology criteria at presentation. There was no retrospective alteration of the diagnosis with the results of gene rearrangement studies or immunophenotyping. Lymphoma was distinguished from lymphoid hyperplasias using algorithms described previously."." Lymphomas of the large cell category encompass lymphomas described in the Working Formulation as large cell and immunoblastic. The distinction between these two histotypes is subjective; features of both are often present in a single tumor, and the clinical relevance of this distinction, even outside of HIV lymphoma, is unclear."." Thus, this biologic continuum representing the diffuse aggressive large cell lymphomas in this paper is simply called large cell. All histologic specimens were reviewed by Dr Ronald Dorfman (Department of Pathology, Stanford University Medical Center, Stanford, CA).
Molecular analysis. Portions of each pretreatment biopsy specimen were sent for routine histologic staining and for molecular studies as previously described."' Homogeneity of tumor involvement in each specimen sent for molecular analysis was confirmed by review of the histologic specimen and by reviewing a frozen section obtained from the specimen sent for molecular studies.
The methods used for DNA blotting for identifying Ig heavy-and light-chain gene rearrangements, for identifying EBV DNA sequences and for evaluating the c-myc gene have been previously described."' Samples containing rearranged JH fragments were categorized as monoclonal B-cell tumors and those with no detectable rearrangement were designated polyclonal, as previously described."'
To test whether the polyclonal lymphomas were truly polyclonal at a molecular level, RT-PCR was performed on RNA extracted from three polyclonal lymphomas and a monoclonal AIDS-associated lymphoma cell line, 2~7 . '~ Consensus V, family-specific signal peptide primers (V,l through VH6) were used as the 5' PCR primer pair and consensus JH region primers were used as the 3' component of the primer pair." RNA was extracted from lymphoma tissue using a single-step isolation procedure2'; cDNA was made using Moloney murine leukemia virus reverse transcriptase (Promega, Madison, PCR amplification was performed on cDNA using a DNA thermal cycler and reagents (Perkin Elmer-Cetus, Norwalk, CT) under the following conditions: denaturation for 1 minute at 94"C, primer annealing for I minute at S S T , and extension for 1 minute at 72°C for 30 cycles. Individual reactions contained final concentrations of 200 pmol/L of each deoxynucleotide triphosphate, 2 U of Taq polymerase, 0.5 to 1 pmol/L of primers, 0.5 to I pg of template DNA. I to 2.5 mmollL MgCI2, 50 mmol/L KCI, IO mmol/L TRIS, pH 8.3, and 0.1 c/o gelatin. PCR products were visualized by ethidium bromide staining of a 2% Nu-sieve agarose (FMC Bioproducts. Rockland. ME)/I $6 agarose gel after the products had been electrophoresed.
Srutisticul rnerhods.
In evaluating the differences between two groups, the chi-square test was used for dichotomous variables. The Wilcoxin test was used for continuous variables, and the log-rank test used for survival times.'" Survival curves were estimated by the Kaplan-Meier procedure.2x Several variables were examined in separate Cox proportional hazards models to determine the effect of each variable on survival time. The effect of different levels of each variable were expressed as a hazard ratio. A risk ratio greater than I indicates higher hazard, and a risk ratio less than 1 indicates improved survival. The risk ratio is the exponentiation of the regression coefficient.
Clonality, presence or absence of EBV, and CD4 lymphocyte count were used as predictors in a multivariate Cox proportional hazards model. Two-way interactions between the three variables were examined one at a time. Each of the baseline clinical and laboratory variables (c-myc, stage, extranodal disease, prior AIDS, cyclophosphamide dose, age, performance score, and lactic dehydrogenase (LDH) were then included in the model to identify any confounding variables.
WI).
RESULTS
Molecular analysis.
Specimens were obtained from 45 individuals. As described in the previous molecular study,"' lymphomas showing absence of a clonal JH rearrangement were defined as polyclonal and those in which a clonal J H rearrangement could be identified were defined as monoclonal. In the sample of 45 patients, 20 lymphomas were identified as monoclonal and 25 as polyclonal.
To confirm the presence of polyclonal B cells within tumors termed polyclonal, RNA was extracted from three lymphomas and subjected to RT-PCR using Ig heavy-chain family specific signal sequence primers and J H consensus primers. Figure 1 shows the ethidium bromide stained gel of PCR products amplified from these lymphomas. Note that the majority of lymphomas had amplifications from multiple V+, families (Fig 1. A through C) and that the broad bands suggested polyclonality in each set of amplified gene products. By comparison. a monoclonal lymphoma (Fig I D) gave a very sharp single V-region product consistent with a monoclonal rearrangement. The use of signal peptide and J,, primers for these amplifications would only have given V,, amplified products from B cells that had actually rearranged their Ig V genes to the J,, locus. The three polyclonal lymphomas gave multiple V,, family amplified products. and by Southern blot analysis showed no distinct rearranged bands (not shown). To test whether amplified V,, gene products would be polyclonal. the V,, amplicans from lymphoma C were cloned and 17 clones were sequenced. All but two of the CDR3 regions were unique, showing that they arose through unique rearrangement events in I6 of I7 R-cell clones. The V,, I segments of 16 of I7 were also unique, and each showed multiple somatic mutations.'" In contrast. the monoclonal tumor ( Fig ID) gave only ;I single VJ specific product and. upon cloning and sequencing. a l l clones were identical." Clirlic.trl c.llNlurctc.ristics. All 45 patients were treated with combination chemotherapy or. in one case. radiotherapy. Eighteen patients were treated with CHOP. 5 with standard-dose mBACOD. 8 with low-dose mBACOD. and a total of I2 patients were treated with COMET-A. One patient with stage 2b disease was treated with involved field radiotherapy. There were three untreated patients who were excludcd from analysis in this study as previously noted. All three had monoclonal disease. were severely ill, and died within 2 weeks of diagnosis.
Pretreatment clinical and laboratory characteristics for the 45 individuals are summarized according to clonality group in Tables I and 2 . C-myc gene rearrangements were exclusively associated with monoclonal tumors. Absolute CD4' lymphocyte counts were significantly higher in those individuals with polyclonal discase. Seventy-nine percent of those with polyclonal tumors had CD4 counts greater than 200/pL. compared with only 35% of those with monoclonal tumors ( P = .OM). Similarly. the median CD4 count was significantly higher in the group with polyclonal disease (277/pL) than in the group with monoclonal disease (123/pL).
There were no significant differences in pretreatment characteristics with respect t o other factors known to be of prognostic valuc in patients with HIV-NHL. Histologic patterns. presence of extranodal sites of disease, prior AIDS-defining opportunistic disease, stage, and cyclophosphamide dosage were all similar in the two clonality groups. Karnofsky performance score was 270% in 75% and 90% of patients with monoclonal and polyclonal disease, respectively. EBV DNA sequences were present in only 9 of 45 (20%) patients overall, and were seen in both polyclonal and monoclonal tumors. Therapeutic response and survival analysis. Complete response was seen in 6 of 19 ( 3 I %) assessable patients with monoclonal disease and in 18 of 23 (78%) assessable patients with polyclonal disease ( P = .002). In patients with advanced stage (111 and IV) disease, 10 of 12 (83%) assessable individuals with polyclonal disease and only 4 of 14 (28%) with monoclonal disease had complete responses to chemotherapy ( P = .02). However, complete response was also highly dependent upon the CD4 lymphocyte count. Complete response was achieved in 13 of 16(81%) patients with CD4 2 200/pL and in only 7 of 21(33%) with CD4 less than 200/yL ( P = .004). There was no relationship between response and any of the other factors listed in Tables 1 and 2 .
Median survival for the group of 45 patients was 6.6 months (range, 0.4 to 40.6). Seven subjects were still alive at the time of data analysis. The average time of observation in this surviving group of seven was 38.1 months (range, 25.9 to 65.2). Subgroup analysis to evaluate the effects of both clonality and CD4 lymphocyte count on survival showed a median survival of 3.5 months in the 15 patients with CD4 less than 200/pL and monoclonal tumor, 5.5 months in those with CD4 less than 200/pL and polyclonal tumor (N = 7). and 4.9 months in those with CD4 greater than 200/pL and monoclonal tumor (N = 4). However, for the group of patients with CD4 greater than 200/pL and polyclonal tumor (N = 13), the median survival was not estimable because more than 50% of the subjects were still alive at the end of the study (range, 25.9 to 65.2 months). All seven surviving patients are in this subgroup. Survival curves for each of the four subgroups are shown in Fig 2, and show significantly longer survival in the group with polyclonal disease and better immune function. Figure 3 shows the histologic characteristics of 6 of the 13 polyclonal lymphomas that occurred in patients with CD4 counts greater than 200/pL. Note the high-grade characteristics as well as prevalent macrophages in this class of lymphoma. Histologically there was no difference between these lymphomas and other large cell lymphomas.
Survival was also significantly influenced by the presence of EBV. Individuals whose tumors contained EBV sequences had a median survival of 3.2 months (range, 0.4 to 19.5), whereas those whose tumors were EBV-had a median survival of 9.0 months (range, 0.7 to 65.2), P = .0007. Twenty-five of 36 (70%) EBV-patients survived for longer than 6 months compared with only 2 of 9 (22%) with EBV' tumors.
All 20 patients with monoclonal disease have died. Seven of 25 (28%) with polyclonal disease are currently living. Although there was a trend toward a greater likelihood of death because of NHL in patients with monoclonal disease ( 1 2/20,60%) as compared with those with polyclonal disease (9/20, 45%), this difference was not statistically significant. The remaining patients with monoclonal disease died of Pneumocystis carinii pneumonia ( l ) , wasting syndrome (3). Staphylococcus aureus sepsis (I), CMV cerebritis ( l ) , and unknown cause (2). The remaining 1 1 patients with polyclonal disease died of P carinii pneumonia (l), wasting syndrome ( 3 ) , CMV disease ( l ) , bacterial pneumonia ( l ) , cryptosporidiosis with wasting (l), auto accident (I), pulmonary Kaposi's sarcoma (l), and unknown cause (2) . A logrank test with non-NHL deaths treated as censored events showed a significant difference in survival between monoclonal and polyclonal subjects ( P = .0007).
A summary of selected clinical and molecular characteristics for each of the 45 individuals ( Table 3 ) 
Proportional hazards analysis.
Variables' were examined in separate Cox proportional hazards models to determine the effect of each variable on survival time (Table 4) . In this univariate analysis monoclonality, the presence of EBV, a lower CD4-positive lymphocyte count, prior AIDSdefining opportunistic disease, poor performance score, and greater number of extranodal sites of lymphoma were all associated with shortened survival. Stage, histologic pattern (large cell v small noncleaved), LDH, and c-myc rearrangement were not predictive of survival. The greatest hazard ratios were associated with clonality, EBV, and CD4 count.
Clonality, presencehbsence of EBV, and CD4 count were then evaluated in a multivariate Cox proportional hazards model to determine independence of factors predictive of survival and to examine two-way interactions between the three variables. This analysis is shown in Table 5 , in which the polyclonal, CD4-greater-than-20pL group is assigned a risk ratio of 1 .O. Here, EBV is shown to be an independent predictor of survival, whereas there is a significant interaction between clonality and CD4 count, as suggested from the survival data. Relative to the polyclonal, CD4-greater- and (F) left neck mass, large cell lymphoma. The abundant cytoplasm is a "plasmacytoid" feature described in elaborate lymphoma classification schemes. Groupings are described in the text.
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DISCUSSION
The results presented indicate that polyclonal HIV-associated NHL is observed predominantly in patients with high CD4 lymphocyte counts and is infrequently associated with the presence of EBV. Individuals with polyclonal disease are more likely to have a complete response to therapy than those with monoclonal disease and those with both polyclonal lymphoma and a CD4 lymphocyte count greater than 200/pL have markedly longer survival than do those in any other CD4 or clonality subgroup. Patients with EBV tumors have the shortest survival, regardless of CD4 count.
Polyclonality in these cases was defined by Southern blot analysis; polyclonal lymphomas were defined as those with no monoclonal rearranged JH band or with a band less intense than a 5% monoclonal control lane.'" The occurrence of polyclonal lymphoproliferative disease in allograft recipients in association with Epstein-Barr virus is well estabpolyclonal B-cell lymphomas in HIV-infected individuals that were less frequently associated with EBV." Other investigators have more recently confirmed the finding of polyclonality using both Southern blot analysis and immunohistochemical techniques."." In this study, we provide additional confirmation of the occurrence of polyclonal lymphoma by using RT-PCR and VH region cloning to show heterogeneous VH family use in three polyclonal lymphomas. The third polyclonal lymphoma contained B cells expressing only VHI, heavy-chain genes. Sequence analysis found 16 of 17 uniquely rearranged VHI family members, proving polyclonality at a nucleotide level.
Southern blots showing the presence of less than 5% of a monoclonal tumor control lane provided the first evidence for the existence of polyclonal lymphomas in AIDS.10,30 The study shown in Fig 1 proves the existence of polyclonal Bcells using a wide range of VH family members. The only way PCR products would have been amplified in this system would be if the B cells had undergone VH gene rearrangement into the J H region. Therefore, all tumor specimens contained B cells. The increased width of the VHamplified gene products in the polyclonal lymphomas also suggests polyclonality with B cells having different-sized CDR3 regions contributing to the PCR product size heterogeneity.
In this patient population, polyclonal disease was associated with a significantly higher CD4 lymphocyte count than monoclonal disease. The reasons for this are unclear. However, recent laboratory findings have suggested that, at some lished.14,15. 17 We have previously reported the existence of level, the development of HIV-associated NHL may be a cytokine-driven pro~ess.~' Polyclonal disease could be a manifestation of cytokine dysregulation occurring early in the course of HIV disease, as reflected in the generalized lymphadenopathy commonly observed in patients with early HIV disease. In other individuals, monoclonal lymphomas may evolve from polyclonal processes later in the course of the disease. This is supported by the finding of individuals at autopsy who have monoclonal disease at some sites and polyclonal disease at other sites3'
The much higher complete response rate seen in patients with polyclonal disease as compared with those with monoclonal tumors may be influenced by the higher CD4 levels observed in the polyclonal group and an ability to better tolerate chemotherapy. However, these findings may also be caused by some inherent differences in the biology of monoclonal and polyclonal tumors.
Although CD4 count was highly predictive of survival, as previously observed: polyclonality was strongly correlated with further improvement in clinical outcome in those patients with CD4 counts greater than 200/pL, as seen in both the Kaplan-Meier survival analysis and the multivariate proportional hazards model. There was no evidence of confounding by any of the other clinical or laboratory factors listed in Table 4 when analyzed in the model. This observation indicates that polyclonal lymphomas are unique in their clinical and biologic behavior. However, it should not be implied from this that HIV-associated polyclonal lymphomas represent a benign lymphoproliferative process because prior autopsy studies have documented this disease as a cause of death in several individuals.?' Polyclonal lymphomas could not be distinguished from monoclonal lymphomas based upon histologic appearance alone. Because the survival of this subpopulation was so unique compared with the remaining population of patients with HIV+ lymphoma, we have included histologic documentation of the aggressive nature of these tumors.
In individuals who have polyclonal disease and high CD4 counts, the precise reasons for improved survival are unclear. It may be that because survival is so short in all patients with low CD4 counts we are unable to detect the contribution of clonality to prognosis in this group.
Despite being present in only a minority of tumors, the presence of EBV DNA sequences was strongly and independently associated with poor survival. Whether this is caused by EBV-associated development of a more biologically aggressive tumor or caused by abnormal immune response to EBV is not known.
The prognosis of patients with B-cell lymphoma in the setting of HIV infection is poor. A variety of clinical prog- -nostic features have been described in several large series of patients with HIV-associated lymphoma^.^-^*^ The presence or absence of a prior AIDS-defining opportunistic disease has been found to be of prognostic importance in two studies:' however, this is most likely related to the underlying level of immune function, or total CD4 count, which is generally lower in those individuals with a prior history of HIV-related illness? Other clinical predictors of survival include performance score,4'* presence or absence of an extranodal site of di~ease,~.' and the intensity of chemotherapy, which appears to have an inverse relationship to ~urvival.~ In one series, the histologic pattern was also an important predictor of survival. 6 Our data indicate that molecular characteristics of the tumors themselves may also be important predictors of clinical outcome.
The value of these findings as they relate to clinical management of HIV-infected individuals with non-Hodgkin's lymphoma remains speculative. Polyclonal lymphoproliferative processes in allograft recipients have, at times, been successfully treated with antiviral agents," although in these cases, the process was generally associated with the presence of EBV sequences. The higher complete response rate in those individuals with polyclonal disease may indicate that less aggressive therapy might be appropriate in this group.
Recent laboratory observations implicating cytokines such as interleukin-6 (IL-6) and IL-103'.33 in the pathogenesis of HIV-NHL may be relevant because these cytokines are potent inducers of B-cell proliferation and could prove to be more important in the pathogenesis of polyclonal lymphoproliferative disease than in monoclonal disease. Thus, polyclonal lymphomas may respond to interventions designed to normalize cytokine production. Future prospective therapeutic trials in this patient population should look closely at the molecular features of these lymphomas and consider stratification for these factors in clinical trial design.
